Cargando…
The impact of medication belief on adherence to infliximab in patients with Crohn’s disease
Objective: Crohn’s disease (CD) is an incurable chronic disease that requires long-term treatment. As an anti-tumor necrosis factor (TNF) agent, Infliximab (IFX) is widely used in the treatment of Crohn’s disease, while the adherence is not high. The purpose of this study was to investigate the adhe...
Autores principales: | Li, Shuyan, Ma, Yan, Sun, Hongling, Ni, Zijun, Hu, Shurong, Chen, Yan, Lan, Meijuan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10461089/ https://www.ncbi.nlm.nih.gov/pubmed/37645443 http://dx.doi.org/10.3389/fphar.2023.1185026 |
Ejemplares similares
-
Medication Belief is Associated with Improved Adherence to Exclusive Enteral Nutrition in Patients with Crohn’s Disease
por: Li, Shuyan, et al.
Publicado: (2021) -
A novel role of the splenic volume in Crohn’s disease: evaluating the efficacy of infliximab
por: Shi, Xuan, et al.
Publicado: (2023) -
Clinical and Immunological Factors Associated with Recommended Trough Levels of Adalimumab and Infliximab in Patients with Crohn’s Disease
por: Orts, Beatriz, et al.
Publicado: (2022) -
The Efficacy of Infliximab Monotherapy versus Infliximab-Azathioprine Sequential Treatment in Crohn's Disease: Experience from a Tertiary Medical Center in China
por: Zhang, Tianyu, et al.
Publicado: (2016) -
Development and Validation of an Interleukin-6 Nomogram to Predict Primary Non-response to Infliximab in Crohn’s Disease Patients
por: Chen, Yueying, et al.
Publicado: (2021)